Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Depreciation & Amortization (CF) (2022 - 2025)

Stoke Therapeutics has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $435000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $435000.0 for Q4 2025, down 17.3% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 17.32% YoY), and the annual figure for FY2025 was $1.8 million, down 17.32%.
  • Depreciation & Amortization (CF) for Q4 2025 was $435000.0 at Stoke Therapeutics, down from $442000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for STOK hit a ceiling of $637000.0 in Q3 2023 and a floor of $247000.0 in Q1 2022.
  • Median Depreciation & Amortization (CF) over the past 4 years was $533000.0 (2024), compared with a mean of $496625.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 141.7% in 2023 and later dropped 18.61% in 2025.
  • Stoke Therapeutics' Depreciation & Amortization (CF) stood at $563000.0 in 2022, then increased by 10.83% to $624000.0 in 2023, then dropped by 15.71% to $526000.0 in 2024, then dropped by 17.3% to $435000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $435000.0 (Q4 2025), $442000.0 (Q3 2025), and $446000.0 (Q2 2025) per Business Quant data.